Vertebral osteomyelitis due to Aspergillus fumigatus in a patient with chronic granulomatous disease successfully treated with antifungal agents and interferon-gamma

References

• Winkelstein JA, Marino MC, Johnston RB Jr . Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155–169.
   PubMed Web of Science ®Google Scholar
• Ahlin A, Boer MD, Roos D . Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr 1995; 84: 1386–1394.
   PubMed Web of Science ®Google Scholar
• Ishibashi F, Nunoi H, Endo F, Matsuda I, Kanegasaki S. Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency. Hum Genet 2000; 106: 473–481.
   PubMed Web of Science ®Google Scholar
• Suliaman F, Amra N, Sheikh S, Almuhsen S, Alsmadi O. Epidemiology of chronic granulomatous disease of childhood in eastern province, Saudi Arabia. Ped Asthma Allerg Immun 2009; 22: 21–26.
   Google Scholar
• Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis 2004; 8: 103–110.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204–3208.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Isturiz RE, Malech HL . Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med1981; 71: 59–66.
   PubMed Web of Science ®Google Scholar
• Tsumura N, Akasu Y, Yamane H . Aspergillus osteomyelitis in a child who has p67-phox-deficient chronic granulomatous disease. Kurume Med J 1999; 46: 87–90.
   PubMedGoogle Scholar
• Dotis J, Panagopoulou P, Filioti J . Femoral osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous disease. Infection 2003; 31: 121–124.
   PubMed Web of Science ®Google Scholar
• Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 1185–1193.
   PubMed Web of Science ®Google Scholar
• Mamishi S, Zomorodian K, Saadat F . A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma. Ann Clin Microbiol Antimicrob 2005;4:4.
   PubMedGoogle Scholar
• Errante PR, Frazão JB, Condino-Neto A. The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov 2008; 3: 225–230.
   PubMedGoogle Scholar
• Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood1992; 79: 1558–1562.
   PubMed Web of Science ®Google Scholar
• Condino-Neto A, Newburger PE. Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation. Blood 2000; 95: 3548–3554.
   PubMed Web of Science ®Google Scholar
• Ishibashi F, Mizukami T, Kanegasaki S . Improved superoxide-generating ability by interferon gamma due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene. Blood 2001; 98: 436–441.
   PubMed Web of Science ®Google Scholar
• The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509–516.
   PubMed Web of Science ®Google Scholar
• Marciano BE, Wesley R, De Carlo ES . Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004; 39: 692–699.
   PubMed Web of Science ®Google Scholar
• Van't Wout JW, Raven EJ, van der Meer JW. Treatment of invasive aspergillosis with itraconazole in a patient with chronic granulomatous disease. J Infect 1990 Mar; 20: 147–150.
   PubMed Web of Science ®Google Scholar
• Van't Hek LG, Verweij PE, Weemaes CM . Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998; 157: 1694–1696.
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, Safdar N. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320–326.
   PubMed Web of Science ®Google Scholar
• Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002; 34: 1415–1417.
   PubMed Web of Science ®Google Scholar